Revolution Medicines, Inc. Common Stock (RVMD) Stock
NASDAQ · RVMD
190.95
Fundamentals
Market cap
$40.93B
Price / Earnings ratio
-23.9x
Price / Sales ratio
N/A
Price / Book ratio
16.2x
Return on assets
-0.6%
Ex-Dividend date
N/A
Last payment date
N/A
Dividend amount
$0.00
Dividend yield
0.0%
Debt / Equity ratio
N/A
Latest news
About Revolution Medicines, Inc. Common Stock
No description available.
SectorHealthcare
IndustryBiotechnology
Employees883
CEODr. Mark A. Goldsmith M.D., Ph.D.
IPO DateFeb 13, 2020
HeadquartersRedwood City, CA
Key Executives
| Name | Title | Year Born |
|---|---|---|
| Dr. Mark A. Goldsmith M.D., Ph.D. | CEO, President & Chairman | 1962 |
| Mr. Jack Anders | Chief Financial Officer | 1977 |
| Ms. Margaret A. Horn J.D. | Chief Operating Officer | 1963 |
| Mr. Jeffrey Cislini J.D. | Senior VP, General Counsel & Corporate Secretary | 1975 |
| Dr. Stephen M. Kelsey FRC Path., FRCP, M.D. | Senior Advisor | 1961 |
| Dr. Martin D. Burke M.D., Ph.D. | Co-Founder & Chairman of Scientific Advisory Board | — |
| Dr. Michael A. Fischbach Ph.D. | Academic Co-Founder & Member of Scientific Advisory Board | 1981 |
| Dr. Kevan M. Shokat Ph.D. | Academic Co-Founder & Member of Scientific Advisory Board | — |
| Mr. Walter Reiher Ph.D. | Chief Information Officer | — |
| Ms. Jan Smith Ph.D. | Chief Scientific Officer | — |
Fundamentals
Valuation
Market cap$40.93B
Price-to-sales ratioN/A
Price-to-book value16.20
Price-earnings ratio-23.90
Return on Equity-83.00%
Return on SalesN/A
Return on AssetsN/A
PEG ratioN/A
Earnings Per Share
Earnings Per Share$-8.85
Income Statement
Average volume1,780,321
EBITDA$-1.32B
1 year high (52w)$224.31
1 year low (52w)$42.18
Dividend
Ex dividend dateN/A
Dividend amount$0.00
Dividend yield0.00%
Last payment dateN/A
Dividend yield (TTM)N/A
Next earnings reportN/A
Solvency
Debt-to-equity ratioN/A



